Compare EIKN & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EIKN | ARVN |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 631.0M | 516.2M |
| IPO Year | 2026 | 2018 |
| Metric | EIKN | ARVN |
|---|---|---|
| Price | $12.48 | $9.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 19 |
| Target Price | ★ $25.60 | $15.05 |
| AVG Volume (30 Days) | 437.0K | ★ 878.2K |
| Earning Date | 03-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | N/A | ★ 1.70 |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.90 | $6.97 |
| 52 Week High | $16.50 | $14.22 |
| Indicator | EIKN | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 56.76 | 60.31 |
| Support Level | $10.82 | $7.90 |
| Resistance Level | $12.16 | $9.65 |
| Average True Range (ATR) | 1.02 | 0.31 |
| MACD | 0.15 | 0.04 |
| Stochastic Oscillator | 40.89 | 77.27 |
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.